Skip to main content
Psychedex
Article

2-MMC Facts

Stimulant; Substituted cathinone; Monoamine releasing agent

Description

2-MMC (2-methylmethcathinone) — ortomephedrone — is a synthetic stimulant of the substituted cathinone class. It floods synapses with dopamine, norepinephrine, and serotonin, producing the drive and euphoria typical of powerful stimulants.[1][2]

Subjective effects include stimulation, euphoria, sociability, appetite suppression, and wakefulness.[3] The experience is that of a restless, drive-focused stimulant — sharper than mephedrone but with less emotional warmth, defined above all by a powerful compulsive redosing urge that shapes the entire session.[4]

2-MMC carries high risk for psychological dependence — its short action, powerful redosing urge, and dopamine-heavy pharmacology drive binge patterns that compound cardiovascular strain[5] and monoamine depletion.[2][4] Treatment-seeking for the closely related 3-MMC rose tenfold in the Netherlands in two years,[4] a measure of the real-world harm.

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 15 mgLight20 – 50 mgCommon50 – 100 mgStrong100 – 135 mgHeavy135+ mg

Starts in 15 – 30 minLasts 2 – 4 hoursAfter-effects 2 – 6 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Negligible
Psychological dependence
High
Withdrawal
Moderate
Compulsive redosing
High

Tolerance

Builds
Moderate
Fully resets after
10 days
Carries over to
amphetamine; methamphetamine; MDMA; 3-MMC; mephedrone; cocaine

Effectslikely at a common dose

Perception
none likely · 8 possible
Body
Appetite suppression; Dry mouth; Heart rate perception changes; Insomnia; Pupil dilation; Stimulation; Wakefulness; +19 possible, including Dehydration sensation, Muscle tension, Vasoconstriction
Thinking
Cognitive euphoria; Thought acceleration; +22 possible, including Compulsive redosing urge, Cognitive dysphoria, Decision impairment
Feeling
Euphoria; +9 possible, including Anhedonia, Anxiety, Depression
Self
none likely · 10 possible, including Craving, Compulsive repetitive behavior, Ego inflation
Time
none likely · 1 possible
Awareness
none likely · 1 possible

Who shouldn't take it

Absolute
Cardiovascular disease; Pregnancy and lactation; Concurrent MAOI therapy
Relative
Seizure disorders; Active psychosis, bipolar disorder, severe anxiety; Hepatic impairment; Vigorous activity in hot environments

Combinations60 recorded

Lethal (1)
MAOIs
Dangerous (25)
Alpha-2 adrenergic receptor antagonist; Amphetamines; Ephedrine, Pseudoephedrine; GHB, Baclofen; GHB, GBL; Local anesthetics; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; SNRIs; SSRIs; Stimulants; 5-HTP, Tryptophan; Antipsychotics; Buspirone; Caffeine; Dopamine agonists; DXM; Ibogaine; Ketamine, DXM, PCP; Lithium; NSAIDs; Psychedelics; and 1 more, see full page
Caution (25)
See full page: psychedex.org/substances/2-mmc
Not graded (9)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Simmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
  2. [2]
    ^abLiechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling — Swiss Medical Weekly doi:10.4414/smw.2015.14043
  3. [3]
    ^KnowDrugs (2024) KnowDrugs: 2-MMC Link
  4. [4]
    ^abcvan Amsterdam J, Nabben T, van den Brink W (2025) Appearance of 2-MMC and 3-MMC on the illicit drug market in the Netherlands: A systematic narrative review of the prevalence and risks — The International journal on drug policy doi:10.1016/j.drugpo.2025.104971
  5. [5]
    ^Groenewegen KL, Gresnigt FMJ, Lonkhuyzen JJN, den Haan C, Franssen EJF, Riezebos RK, Ohana D, de Lange DW (2024) Cardiotoxicity After Synthetic Cathinone Use; Two Cases, A Case Series and Scoping Review — Cardiovascular toxicology doi:10.1007/s12012-024-09832-x
Print version
Report an issue